Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


1. Nx-5948
2. 2649400-34-8
3. Btk-in
4. Schembl23484815
5. Gtpl12898
6. Ex-a7961
7. Nx5948
8. At41582
9. Compound 195 [wo2021113557a1]
10. Hy-153321
11. Cs-0676328
12. 3-((4-(1-((1-(6-(((s)-2,6-dioxopiperidin-3-yl)carbamoyl)pyridin-3-yl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)-5-((r)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl)pyrazine-2-carboxamide
13. 3-[4-[1-[[1-[6-[[(3s)-2,6-dioxopiperidin-3-yl]carbamoyl]pyridin-3-yl]piperidin-4-yl]methyl]piperidin-4-yl]anilino]-5-[(3r)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]pyrazine-2-carboxamide
| Molecular Weight | 807.0 g/mol |
|---|---|
| Molecular Formula | C42H54N12O5 |
| XLogP3 | 2.6 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 11 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 202 |
| Heavy Atom Count | 59 |
| Formal Charge | 0 |
| Complexity | 1500 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
29
PharmaCompass offers a list of NX-5948 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right NX-5948 manufacturer or NX-5948 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred NX-5948 manufacturer or NX-5948 supplier.
PharmaCompass also assists you with knowing the NX-5948 API Price utilized in the formulation of products. NX-5948 API Price is not always fixed or binding as the NX-5948 Price is obtained through a variety of data sources. The NX-5948 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Bexobrutideg manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bexobrutideg, including repackagers and relabelers. The FDA regulates Bexobrutideg manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bexobrutideg API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Bexobrutideg supplier is an individual or a company that provides Bexobrutideg active pharmaceutical ingredient (API) or Bexobrutideg finished formulations upon request. The Bexobrutideg suppliers may include Bexobrutideg API manufacturers, exporters, distributors and traders.
click here to find a list of Bexobrutideg suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bexobrutideg as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Bexobrutideg API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Bexobrutideg as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Bexobrutideg and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Bexobrutideg NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Bexobrutideg suppliers with NDC on PharmaCompass.
Bexobrutideg Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bexobrutideg GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bexobrutideg GMP manufacturer or Bexobrutideg GMP API supplier for your needs.
A Bexobrutideg CoA (Certificate of Analysis) is a formal document that attests to Bexobrutideg's compliance with Bexobrutideg specifications and serves as a tool for batch-level quality control.
Bexobrutideg CoA mostly includes findings from lab analyses of a specific batch. For each Bexobrutideg CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bexobrutideg may be tested according to a variety of international standards, such as European Pharmacopoeia (Bexobrutideg EP), Bexobrutideg JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bexobrutideg USP).